UK’s CMA Issues Fines Over Fludrocortisone
Amilco, Aspen And Tiofarma Named In UK Investigation
Executive Summary
The UK’s Competition and Markets Authority has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.
You may also be interested in...
Tiofarma Admits Involvement On UK Fludrocortisone
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.
UK’s CMA Reveals Details Of Fludrocortisone Probe
The UK’s CMA has accused Tiofarma and Amilco of colluding with Aspen over an illegal agreement that resulted in significant price hikes for fludrocortisone.
UK’s BGMA Condemns Anti-Competitive Behavior
The BGMA has condemned anti-competitive behavior in the UK after Aspen paid the NHS £8m in a landmark case over “illegal market sharing”.